Insight & Intelligence

More »

Feature Articles

More »

For full access to this article login to GEN Select now.

June 01, 2009 (Vol. 29, No. 11)

Overcoming Protein Production Hurdles

Increasing Capabilities Becomes Essential as the Biologics Market Grows Rapidly

  • Recombinant antibodies have emerged as dominant players in the biopharma industry despite the copious quantities required for treatment. Although nonantibody biologics are typically produced at much smaller scale, are less complex, and have limited secondary modifications, their production is also fraught with challenges. Not surprisingly overcoming protein-production hurdles was ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.

Be sure to take the GEN Poll

{{ vm.poll.Title }}

More »